H.C. Wainwright analyst Andrew Fein maintained a Hold rating on Aimmune Therapeutics (NASDAQ:AIMT) on Tuesday, setting a price target of $15, which is approximately 16.57% below the present share price of $17.98.
Fein expects Aimmune Therapeutics to post earnings per share (EPS) of -$1.34 for the second quarter of 2020.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Aimmune Therapeutics, with an average price target of $35.75.
The analysts price targets range from a high of $66 to a low of $15.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $575 thousand and a net profit of -$85.28 million. The company's market cap is $1.22 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 11.4% and a 50.11% success rate.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.